Head to Head Analysis: Aptevo Therapeutics (NASDAQ:APVO) versus Johnson & Johnson (NYSE:JNJ)

Aptevo Therapeutics (NASDAQ:APVO) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Aptevo Therapeutics and Johnson & Johnson, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	0	0	1	0	3.00
Johnson & Johnson	0	11	7	2	2.55

Aptevo Therapeutics presently has a consensus target price of $219,040.00, suggesting a potential upside of 4,424,950.51%. Johnson & Johnson has a consensus target price of $170.88, suggesting a potential upside of 10.23%. Given Aptevo Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Aptevo Therapeutics is more favorable than Johnson & Johnson.

Institutional and Insider Ownership

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 0.0% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Aptevo Therapeutics and Johnson & Johnson’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-488.93%	-152.51%
Johnson & Johnson	18.20%	34.24%	13.63%

Risk & Volatility

Aptevo Therapeutics has a beta of 5.75, suggesting that its stock price is 475% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.

Valuation & Earnings

This table compares Aptevo Therapeutics and Johnson & Johnson”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	$3.11 million	0.64	-$24.13 million	N/A	N/A
Johnson & Johnson	$89.33 billion	4.18	$14.07 billion	$8.99	17.24

Johnson & Johnson has higher revenue and earnings than Aptevo Therapeutics.

Summary

Johnson & Johnson beats Aptevo Therapeutics on 10 of the 13 factors compared between the two stocks.

About Aptevo Therapeutics

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.